Imagen de Portada

Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Binayak Sinha, Samit Ghosal
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Obesity
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
por: Giorgia Rutigliani, et al.
Publicado: (2026)

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs
por: Jirawan Vienghirun, et al.
Publicado: (2026)

Weight Loss Outcomes Between GLP ‐1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta‐Analysis and Meta‐Regression
por: Muhammad Tahir, et al.
Publicado: (2026)

Weight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
por: Michael Lim, et al.
Publicado: (2026)

One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment
por: Joachim Holt, et al.
Publicado: (2025)

GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation
por: Haisheng Wu, et al.
Publicado: (2026)

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
por: Lasin Ozbek, et al.
Publicado: (2026)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
por: Roberta Scairati, et al.
Publicado: (2026)

Glucagon‐Like Peptide‐1 Receptor Agonists: Considerations for Treating Preconception Obesity
por: Lauren T. Berube, et al.
Publicado: (2026)

GLP‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation
por: Hao Dai, et al.
Publicado: (2025)

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials
por: Lucas Sabatella, et al.
Publicado: (2025)

Micronutrient and Nutritional Deficiencies Associated With GLP ‐1 Receptor Agonist Therapy: A Narrative Review
por: Jorge Urbina, et al.
Publicado: (2026)

Weekly Subcutaneous VK2735 , a GIP / GLP ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study
por: Harold E. Bays, et al.
Publicado: (2026)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
por: Inyoung Hwang, et al.
Publicado: (2026)

GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
por: Cynthia F. X. C. A. Silva, et al.
Publicado: (2026)

GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
por: Hiba Jebeile, et al.
Publicado: (2025)

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
por: Tahmid Hussain, et al.
Publicado: (2026)

Obesity and Female Reproductive Health; Is There a Role for Glucagon‐Like Peptide‐1 Receptor Agonists?
por: Rachel Roberts, et al.
Publicado: (2025)

Impact of GLP ‐1 Receptor Agonist Discontinuation on Liver‐Related Parameters: A Systematic Review and Meta‐Analysis
por: Matheus Souza, et al.
Publicado: (2026)

Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
por: Rayanne Santos de Paulo, et al.
Publicado: (2026)

Trends in Weight Loss Attempts and Strategies Among US Adolescents With Overweight or Obesity
por: Ligang Liu, et al.
Publicado: (2026)

Beyond GLP ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
por: Mikhail Khachaturov, et al.
Publicado: (2026)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes
por: Ying Lu, et al.
Publicado: (2025)

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults
por: Jie‐Syuan Wu, et al.
Publicado: (2026)

Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study
por: G. Caleb Alexander, et al.
Publicado: (2025)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
por: Hezekiah C. T. Au, et al.
Publicado: (2026)

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
por: Yazan Alhamdan, et al.
Publicado: (2026)

Combining GLP ‐1 Receptor Agonists and Health‐Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real‐World Single‐Center Study
por: Julia Lischka, et al.
Publicado: (2026)

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non‐Diabetic Adults: A Meta‐Analysis of Randomised Controlled Trials
por: Muhammad Hassan Azam, et al.
Publicado: (2026)

Optimizing Obesity Management With GLP‐1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review
por: Elizabeth Sharp Edens, et al.
Publicado: (2026)

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
por: Andreea Ciudin, et al.
Publicado: (2026)

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea
por: Bei‐Bei Qian, et al.
Publicado: (2025)

Methodological Concerns Regarding BMI Imbalance and Competing Risks in a Head‐to‐Head Comparison of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists for Incident Dementia
por: Shio‐Shin Jean, et al.
Publicado: (2026)

RETRACTION : Effects of GLP ‐1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis Based on Randomized Controlled Trials
Publicado: (2026)

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
por: Timothy H. Chan, et al.
Publicado: (2026)

Impact of Weight Management Advice From Healthcare Providers on Weight Loss in Individuals With Type 2 Diabetes and Overweight or Obesity
por: Xiaoyue Zhang, et al.
Publicado: (2026)

Cardiometabolic Profiles and Treatment Trajectories of GLP ‐1 Receptor Agonist Users With Obstructive Sleep Apnea: Real‐World Evidence From a Large Private Healthcare Cohort in Poland
por: Klaudia Nowak, et al.
Publicado: (2026)

How Bioethics and Reproductive Justice Ought to Inform Glucagon‐Like Peptide‐1 Receptor Agonists, Research, and Pregnancy
por: Nishita Pondugula, et al.
Publicado: (2025)

Efficacy of Interventions to Promote Exercise Adherence in People With Overweight or Obesity: A Systematic Review
por: Matheus de Sena Anchieta Rodrigues, et al.
Publicado: (2026)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review
por: Flavio T. Vieira, et al.
Publicado: (2026)